12,372 trials
Breast Carcinoma · Ductal Breast Carcinoma In Situ · Hot Flashes
Primary: Average Change in Hot Flash Activity Score From Baseline to Week 7 for Low Dose Oxybutynin vs Placebo and for High Dose Oxybutynin vs Placebo — -16.9; -10.6; -5.7 score…
End Stage Renal Disease (ESRD) · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
Urinary Bladder, Overactive
Primary: Treatment Phase 1 (Treatment Cycle 1): Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes at Week 12 After the First Treatment — -1.25…
ESRD · Diabetes
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
Diabetes Mellitus, Type 1
Primary: Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT) — 0.773; 0.791; 0.782; 0.788 mm
Cardiac Catheterisation
Primary: Pain Assessment Using Visual Analogue Scale — 24.75; 24.74 score on a scale
Diabetic Macular Edema
Primary: Maximum Concentration (Cmax) of Anti-VEGF Antibody — 25.22; 9.56 ng/mL
Stroke With Hemiparesis
Primary: Time Taken to Form a Stable Grasp Pre-Treatment — 1.51; 1.14 Preload phase duration in Seconds
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Primary: Number of Participants Having Reached the Composite Efficacy Endpoint of Biopsy-proven Acute Rejection — 5; 3; 5; 5 Participants — p=0.9712
Healthcare-Associated Pneumonia · Ventilator-Associated Pneumonia · Lung Diseases
Primary: Percentage of Participants With All Cause Mortality in the Intent-to-Treat (ITT) Population - Day 28 — 24.0; 25.3 Percentage of Participants
Chronic Kidney Disease · End Stage Renal Failure on Dialysis · Anemia
Primary: Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period — 4.695; 4.641 gram per liter
Insulin Hypoglycemia · Type 1 Diabetes Mellitus · Severe Hypoglycemia
Primary: Number of Subjects With a Positive Glucose Response — 76; 78 Participants
Psoriasis
Primary: Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16 — 2.0; 73.2 percentage of…
Osteoporosis in Men
Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12 — 1.2; 12.1 percent change — p=< 0.0001
Psoriasis
Primary: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A) — 47.4; 72.4 percentage of…